Physician profile
Blake Bond
NPI 1053605493
$640.00
in general payments reported to CMS, 2019-2025
15 companies · $85.39 in 2025
The $85.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.63 · 2020: $138 · 2021: $192 · 2022: $67.25 · 2023: $84.18 · 2024: $43.89 · 2025: $85.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.22 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $73.35 | 2020-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $71.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $67.38 | 2020-2021 | |
| Abbvie INC. | $67.31 | 2021-2024 | |
| Novo Nordisk INC | $31.94 | 2020-2021 | |
| Pfizer INC. | $30.68 | 2023 | |
| Sanofi Pasteur INC. | $26.88 | 2023 | |
| Sumitomo Pharma America, INC. | $26.02 | 2024 | Gemtesa |
| Stryker Corporation | $22.75 | 2025 | Accolade, Triathlon, Mako |
| Genentech USA, INC. | $18.18 | 2020 | |
| Merck Sharp & Dohme LLC | $17.68 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2025 | |
| Glaxosmithkline, LLC. | $16.75 | 2025 | Shingrix |
| Phadia US INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.